Treatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation

Article


Novoselova, T., Margulis, B., Novoselov, S., Sapozhnikov, A., Van Der Spuy, J., Cheetham, M. and Guzhova, I. 2005. Treatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation. Journal of Neurochemistry. 94 (3), pp. 597-606. https://doi.org/10.1111/j.1471-4159.2005.03119.x
TypeArticle
TitleTreatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation
AuthorsNovoselova, T., Margulis, B., Novoselov, S., Sapozhnikov, A., Van Der Spuy, J., Cheetham, M. and Guzhova, I.
Abstract

The accumulation of insoluble protein aggregates is a feature of neurodegenerative disease. Overexpression of Heat Shock Protein 70 (HSP70) can protect cells with protein aggregates from apoptosis. Another trait of HSP70 is its ability to cross the plasma membrane. Therefore, we purified a preparation of HSP70/HSC70 from bovine muscle and used it in a model of Huntington's disease. Human neuroblastoma SK-N-SH cells were transfected with huntington exon 1 with short (25) or long (103) CAG trinucleotide repeats coupled to green flourescent protein (GFP). Cells transfected with the long polyCAG repeat had insoluble protein aggregates and died through apoptosis. Biotinylated HSP70/HSC70 incorporated into the culture medium appeared inside the cells within 3-6 h of incubation. This incorporation correlated with a reduction in apoptotic cells by 40-50%. Confocal microscopy revealed that labelled internalized HSP70/HSC70 co-localized with the polyglutamine inclusions. The measurement of the number and size of inclusions showed that HSP70/HSC70 was able to reduce both these parameters. A filter trap assay and immunoblotting demonstrated that the introduction of HSP70/HSC70 also decreased protein aggregation. Together with earlier data on the effects of exogenously administered HSP70/HSC70 on cultured cells and on animals, these data show that preparations based on HSP70 may have some potential as therapies for a variety of neurodegenerative pathologies.

PublisherWileyBlackwell
JournalJournal of Neurochemistry
ISSN0022-3042
Electronic1471-4159
Publication dates
Online30 Jun 2005
Print30 Jun 2005
Publication process dates
Deposited11 Nov 2019
Accepted24 Jan 2005
Output statusPublished
Digital Object Identifier (DOI)https://doi.org/10.1111/j.1471-4159.2005.03119.x
LanguageEnglish
Permalink -

https://repository.mdx.ac.uk/item/88937

  • 13
    total views
  • 0
    total downloads
  • 0
    views this month
  • 0
    downloads this month

Export as